Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.
Tralokinumab may be a viable option for patients with moderate to severe atopic dermatitis.
In a recent interview with HCPLive®, Kim Kjøller, MD, executive vice president of global research & development at LEO Pharma, explained 3 trials, ECZTRA1, 2, and 3, all testing the efficacy of tralokinumab.
ECZTRA1 and 2 were mono trials, meaning the primary endpoint was at week 16 on tralokinumab alone, then patients were followed for up to 52 weeks of treatment. The protocol was very strict, so if the patient only smeared themselves only once with the topical steroid over the 16 weeks, they were considered non-responders.
“What we saw there was a good, robust signal for tralokinumab, clear separation from placebo, and importantly, that improvement continued on,” he said.
One of the hallmarks for tralokinumab was when investigators looked at the study period, of those responding from week 16 to week 52, 51% and 59%, respectively, responding. And that was without using a topical steroid.
Patients were able to maintain the benefits with Q4 dosing, when typically, the standard dose is Q2.
ECZTRA3 more mimicked real life, he said. Patients were using a topical steroid alongside tralokinumab, and investigators saw 39% of patients achieve almost clear skin at week 16. The study was only continued until week 32.
“The ability to maintain that response was really strong, with more than 90% of patients actually maintaining response between week 16 and 32,” Kjøller, MD, said.